ÓSKARE CAPITAL STRENGTHENS TEAM WITH TWO NEW MEMBERS:
Oliver Lamb – MSc (Co-Founder and Investment Manager)
Dr. Zsolt Lenkei – MD, PhD. (Operating Partner)
Wednesday, October 7th 2020
Oliver Lamb MSc is an investment professional and long-time Agri Tech and Cannabis consultant, serving as Director and Board Member to companies in the European market. Founder of the consultancy and accelerator, Bloom Innovation, Lamb brings a strong pipeline of European dealflow and an analytical perspective gained from his time developing market monitoring algorithms at Morgan Stanley. Lamb will be identifying investment targets, conducting due diligence and assisting in the execution of transactions and development of portfolio companies. Lamb will also be helping to build out Óskare’s upcoming accelerator.
Dr. Zsolt Lenkei is a medical doctor and neuroscientist, and one of the leading experts in the functioning of the endocannabinoid system. Dr. Lenkei has been a pioneer in European cannabinoid research on the CNS system and cellular function. He is the Director of the DYNAMICS OF NEURONAL STRUCTURE IN HEALTH AND DISEASE laboratory at INSERM and was the Co-Chair of the 2019 Gordon Conference on Cannabinoid Function in the CNS. He is also the Co-Founder of Iconeus, a company developing a novel ultrasound brain imaging technique. Dr. Lenkei will be assisting the fund in identifying investment targets, conducting due diligence, sitting on the Óskare Capital Scientific Advisory Board as well as helping portfolio companies.
ABOUT OSKARE CAPITAL and OSKARE FUND I:
Launched in late June 2020, ÓSKARE Fund 1, domiciled in Ireland, is Europe’s first AIFM and ESG compatible specialised fund dedicated to the development of the medical cannabis industry with a focus on Europe. The team is now fundraising for Óskare Fund l (€150m fund size) with a first close planned in Q4 2020 of €50m.
ÓSKARE CAPITAL will not directly invest in opportunities related to the recreational cannabinoid market. Rather, the fund will prioritize investments in the medical cannabinoid sector where there is an immense therapeutic potential (e.g. pain, MS, oncology, spasticity, Autism spectrum disorder, ADHD, …).
There is strong scientific rationale to utilize cannabinoids as substitutes for a diverse range of existing therapeutic offerings including medical treatments that modulate and take advantage of the endocannabinoid system.
The fund will invest in life sciences/therapeutics but also across the entire value chain, including in products, agricultural/ industrial solutions and services critical to the medical cannabis ecosystem and infrastructure. These investment opportunities exist and are developing in Europe/UK at a fast pace.
We’ve brought together a talented team that is globally unequalled and includes established European deeptech and life sciences VCs, medical and pharma industry professionals as well as non-executive chairman Bruce LINTON, former CEO and founder of Canopy Growth.
We have assembled an advisory board supported by Dr. Olivier BRANDICOURT, former CEO of Sanofi, CEO Bayer HealthCare AG and C-Level executive at Pfizer. The team and its advisors can be found at https://oskarecapital.com/team/.
A constant flow of announcements regarding the changing regulatory and legal status in Europe in the last 3 years are creating the biggest legal medical platform in the world. It is a high growth market predicted to grow to €2.8b in 2024 and €15b in 2029 and Europe has seen an increase in research institutes and companies in this market that require funding.
The pipeline of disruptive solutions and emerging technologies that we have developed over the last 12 months within the EU/UK is very strong. We have over 350 companies in our pipeline with some ready to be funded now and the market is expanding quickly1.
The Fund’s mission is particularly pertinent to one of Óskare’s team members who has a child suffering from a rare genetic disorder where parents of these children treat ADHD and Anxiety with CBD oil with good results. A well-documented case of the potential of medical cannabinoids is in the treatment of Dravet Syndrome (childhood epilepsy), where medical cannabis has significantly improved the lives of children suffering from this condition (and parents who treat them).
In a landscape of volatile public markets and low valuations in the early-stage private markets, we have a compelling investment thesis and a globally unequalled team to deliver on this next and sustainable growth theme, with excellent prospects of obtaining a Tier 1 return for investors.
Visit our website at oskarecapital.com
1Germany implemented medical cannabis in 2017, in 2019 there were over 200 MEUR in medical cannabis reimbursements and 2020 is expected be between 400-500 MEUR in size